Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELGRAFT in Chronic Diabetic Foot Ulcers
NCT07498218Phase 1Recruiting
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Modality
- Stem Cell Therapies, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Velgraft in diabetic foot ulcer (DFU) (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 169 days. Started Mar 2026; status: recruiting.
02
Drugs
Velgraft
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT07498218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498218.